Science 37 Holdings, Inc (SNCE) News
Filter SNCE News Items
SNCE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SNCE News Highlights
- For SNCE, its 30 day story count is now at 2.
- Over the past 3 days, the trend for SNCE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest SNCE News From Around the Web
Below are the latest news stories about SCIENCE 37 HOLDINGS INC that investors may wish to consider to help them evaluate SNCE as an investment opportunity.
Science 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"Science 37's unified platform that powers the Metasite receives award for outstanding digital health and technology innovationRESEARCH TRIANGLE PARK, N.C., May 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, has been named the winner of the prestigious "Best Overall Clinical Trial Platform" award in the 7th annual MedTech Breakthrough Awards program. Science 37 was chosen by MedTech Breakthrough, an autonomous market intell |
Science 37 Reports First Quarter 2023 Financial ResultsRESEARCH TRIANGLE PARK, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter ended March 31, 2023. “First quarter results reflected continued progress with our key strategic initiatives,” stated David Coman, Chief Executive Officer of Science 37. “Our recent actions to reduce our cost structure and increase focus on our unique Metasite solution position us well to driv |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time for another dive into the biggest pre-market stock movers traders need to know about as we cover the winners and losers for Friday! |
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a mate |
Science 37 Joins Partnership in Support of White House CancerX and Cancer MoonshotStrategic partnership will leverage Science 37’s leadership in remote and hybrid clinical research to enable expansive clinical trial access for oncology patientsRESEARCH TRIANGLE PARK, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading MetasiteTM, today announced its partnership with the Digital Medicine Society (DiMe) in support of the CancerX inaugural project. Answering the call of the White House, Science 37 will join DiMe and Moffitt Cance |
Science 37 to Report First Quarter 2023 Financial Results on May 15, 2023RESEARCH TRIANGLE PARK, N.C., May 01, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report first quarter 2023 financial results prior to the market open on Monday, May 15, 2023. The Science 37 management team will host a conference call to discuss these results on May 15, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using th |
Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, DiversityNew role supports the Company’s objective to lead the industry with faster, more inclusive clinical researchRESEARCH TRIANGLE PARK, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, announced today Erica Prowisor as SVP of Patient and Provider Networks to accelerate patient recruitment, ensure participant diversity and gain operational efficiencies. Erica has been forging new ground as a leader in patient recruitment for nearly 20 |
Science 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical ResearchRESEARCH TRIANGLE PARK, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced a multi-year relationship with Amazon Web Services (AWS) to scale and accelerate adoption of the Science 37 Metasite, which provides clinical trial sponsors the ability to securely engage with patients beyond traditional clinical trial sites. Science 37 will become a partner in the AWS Partner Network (APN), which will help r |
Science 37 Adds New Head of Quality, Irena LambridisNew role supports the Company’s objective to be the DCT industry’s “undisputed leader” in qualityRESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance. Irena will be responsible for overseeing quality and compliance across all functions, including the Company's newly announced global Centers of Excellence in I |
Science 37 to Host Business Update Call on April 12, 2023RESEARCH TRIANGLE PARK, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will host a business update conference call prior to the market open on Wednesday, April 12, 2023. The Science 37 management team will host a conference call to discuss the business update on April 12, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) or |